446 related articles for article (PubMed ID: 26469273)
1. Edaravone, a Free Radical Scavenger, Delayed Symptomatic and Pathological Progression of Motor Neuron Disease in the Wobbler Mouse.
Ikeda K; Iwasaki Y
PLoS One; 2015; 10(10):e0140316. PubMed ID: 26469273
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
;
Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective effect of ultra-high dose methylcobalamin in wobbler mouse model of amyotrophic lateral sclerosis.
Ikeda K; Iwasaki Y; Kaji R
J Neurol Sci; 2015 Jul; 354(1-2):70-4. PubMed ID: 25982504
[TBL] [Abstract][Full Text] [Related]
4. Edaravone: a new hope for deadly amyotrophic lateral sclerosis.
Bhandari R; Kuhad A; Kuhad A
Drugs Today (Barc); 2018 Jun; 54(6):349-360. PubMed ID: 29998226
[TBL] [Abstract][Full Text] [Related]
5. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice.
Ito H; Wate R; Zhang J; Ohnishi S; Kaneko S; Ito H; Nakano S; Kusaka H
Exp Neurol; 2008 Oct; 213(2):448-55. PubMed ID: 18718468
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study).
Yoshino H; Kimura A
Amyotroph Lateral Scler; 2006 Dec; 7(4):241-5. PubMed ID: 17127563
[TBL] [Abstract][Full Text] [Related]
7. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation).
WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 18 STUDY GROUP
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):40-48. PubMed ID: 28872915
[TBL] [Abstract][Full Text] [Related]
8. Free-radical scavenger edaravone inhibits both formation and development of abdominal aortic aneurysm in rats.
Morimoto K; Hasegawa T; Tanaka A; Wulan B; Yu J; Morimoto N; Okita Y; Okada K
J Vasc Surg; 2012 Jun; 55(6):1749-58. PubMed ID: 22341578
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis.
Sawada H
Expert Opin Pharmacother; 2017 May; 18(7):735-738. PubMed ID: 28406335
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Edaravone in Amyotrophic Lateral Sclerosis Patients in Indian Population.
Tomar S; Gupta S; Singal A; Soni R
J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443425
[TBL] [Abstract][Full Text] [Related]
11. Post-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double-blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosis.
Takahashi F; Takei K; Tsuda K; Palumbo J
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):32-39. PubMed ID: 28872914
[TBL] [Abstract][Full Text] [Related]
12. Edaravone and its clinical development for amyotrophic lateral sclerosis.
Takei K; Watanabe K; Yuki S; Akimoto M; Sakata T; Palumbo J
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):5-10. PubMed ID: 28872907
[TBL] [Abstract][Full Text] [Related]
13. Neuronal nitric oxide synthase inhibitor, 7-nitroindazole, delays motor dysfunction and spinal motoneuron degeneration in the wobbler mouse.
Ikeda K; Iwasaki Y; Kinoshita M
J Neurol Sci; 1998 Sep; 160(1):9-15. PubMed ID: 9804111
[TBL] [Abstract][Full Text] [Related]
14. Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger.
Aoki M; Warita H; Mizuno H; Suzuki N; Yuki S; Itoyama Y
Brain Res; 2011 Mar; 1382():321-5. PubMed ID: 21276427
[TBL] [Abstract][Full Text] [Related]
15. Edaravone, a free radical scavenger, protects against retinal damage in vitro and in vivo.
Inokuchi Y; Imai S; Nakajima Y; Shimazawa M; Aihara M; Araie M; Hara H
J Pharmacol Exp Ther; 2009 May; 329(2):687-98. PubMed ID: 19201991
[TBL] [Abstract][Full Text] [Related]
16. Edaravone for the treatment of amyotrophic lateral sclerosis.
Yoshino H
Expert Rev Neurother; 2019 Mar; 19(3):185-193. PubMed ID: 30810406
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation.
Peviani M; Salvaneschi E; Bontempi L; Petese A; Manzo A; Rossi D; Salmona M; Collina S; Bigini P; Curti D
Neurobiol Dis; 2014 Feb; 62():218-32. PubMed ID: 24141020
[TBL] [Abstract][Full Text] [Related]
18. A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis.
EDARAVONE (MCI-186) ALS 16 STUDY GROUP
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):11-19. PubMed ID: 28872917
[TBL] [Abstract][Full Text] [Related]
19. Enhanced oxidative stress and the treatment by edaravone in mice model of amyotrophic lateral sclerosis.
Ohta Y; Nomura E; Shang J; Feng T; Huang Y; Liu X; Shi X; Nakano Y; Hishikawa N; Sato K; Takemoto M; Yamashita T; Abe K
J Neurosci Res; 2019 May; 97(5):607-619. PubMed ID: 30565312
[TBL] [Abstract][Full Text] [Related]
20. Atorvastatin treatment attenuates motor neuron degeneration in wobbler mice.
Iwamoto K; Yoshii Y; Ikeda K
Amyotroph Lateral Scler; 2009; 10(5-6):405-9. PubMed ID: 19922131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
